Correction to: Drugs (2021) 10.1007/s40265-021-01626-7
Authorship and Conflict of Interest statement, first sentence, which currently reads:
During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on the article.
Should read:
During the peer review process, Celltrion Healtcare Co., Ltd, was offered an opportunity to comment on the article.
This is to clarify that Celltrion Healthcare Co., Ltd and not Celltrion Inc., the manufacturer of the agent reviewed, was approached for the review process.
The original article has been updated.